Channel NewsAsia
| 11 months ago
German pharmaceuticals maker Merck KGaA said on Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients. The trials found that in combination with standard chemotherapy, Erbitux did not extend "...